Least surprising headline of the week. Er, last week. Okay, two weeks ago.
Joe G. sent this in on April 12, saying, "My friends who
suffer from schizophrenia deserve better than treatment predicated on
self-serving research."
From the piece in the Washington Post:
In fact, when psychiatrist John Davis analyzed every publicly available trial funded by the pharmaceutical industry pitting five new antipsychotic drugs against one another, nine in 10 showed that the best drug was the one made by the company funding the study.
Comparison of Schizophrenia Drugs Often Favors Firm Funding Study
